Background: Repetitive transcranial magnetic stimulation (rTMS) is frequently used as an adjunctive treatment with antidepressants for depression. We aimed to evaluate the clinical efficacy and safety of antidepressant classes when administered concurrently with rTMS for the management of major depressive disorder (MDD)., Methods: In this systematic review and meta-analysis, MEDLINE, Embase, PsycINFO, and the Cochrane Library were searched from inception to April 12th 2024 for terms relating to medication, depression, and rTMS and appraised by 2 independent screeners. All randomized clinical trials that prospectively evaluated a specific antidepressant adjunctively with sham rTMS as a control in MDD were included. The study was registered with PROSPERO (CRD42023418435). The primary outcome measure assessed symptomatic improvement measured by formal depression scales. We used a random-effects model with pooled Standardized Mean Differences (SMDs) and log odds ratios (OR). All studies were assessed for their methodological quality and bias using the Cochrane Collaboration Risk of Bias tool version 2 (RoB2)., Findings: 14 articles from 5376 identified studies were included in the systematic review and meta-analysis. There was only sufficient trial data to evaluate the effects of rTMS and combination therapy with selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs). Across studies, 848 participants (mean [SD] age:41.1 [18.7] years for SSRIs, 51.8 [3.8] years for SNRIs) prospectively examined the efficacy of antidepressant medication with rTMS. Combining rTMS with SSRIs led to significantly lower depression scores, (SMD [CI] of -0.65 [-0.98, -0.31], p = 0.0002, I 2 = 66.1%), higher response (OR = 0.97 [0.50, 1.44], p < 0.0001, I 2 = 25.33%) and remission rates (OR = 1.04 [0.55, 1.52], p < 0.0001, I 2 = 0.00%) than medication with sham rTMS. No additive benefit was found for SNRIs with rTMS (SMD of 0.10 [-0.14, 0.34], p = 0.42, I 2 = 0.00%; OR = 0.12 [-0.39, 0.62], p = 0.64, I 2 = 0.00%; OR = -0.31 [-0.90, 0.28], p = 0.86, I 2 = 39.9%). The overall risk of bias for the included studies ranged from low to high, with 1 study having a high risk of bias., Interpretation: The combination of rTMS with SSRIs, but not SNRIs, significantly reduced depression severity, increasing response and remission rates. Some analyses demonstrated high heterogeneity, which was influenced by an SSRI trial with a high effect size. Overall, these results suggest that not all antidepressant combination therapies are alike, and SSRIs should be considered when initiating rTMS., Funding: Donald T. Stuss Young Investigator Research Innovation Award from the Sandra Black Centre for Brain Resilience & Recovery and the Harquail Centre for Neuromodulation through the Sunnybrook Foundation., Competing Interests: SMN has received research support from Brain Canada, CIHR, the Brain and Behaviour Research Foundation, Tory Trauma Program at Sunnybrook Health Sciences Centre, and he is affiliated with the Ontario Ketamine and Infusion Clinic. He reports no conflicts of interest with the current work. PG has received grants in the area from CIHR and Physician Services Incorporated. He is the DSMB chair for an intravenous ketamine for life depression study. He receives salary support from the University of Toronto, Department of Psychiatry, Academic Scholar Award; he has provided consulting services for Abbott. He reports no conflicts of interest with the current work. JSR has received support from the Harquail Centre for Neuromodulation, the Dr. Sandra Black Centre for Brain Resilience & Recovery and CIHR. She reports no conflicts of interest with the current work. CH has received support from the Harquail Centre for Neuromodulation and CIHR. He reports no conflicts of interest with the current work. WS has received support from CIHR, NSERC, the Alzheimer’s Association & Brain Canada, Weston Brain Institute & Alzheimer’s Research UK, Alzheimer’s Association, and Michael J. Fox Foundation. He reports no conflicts of interest with the current work. All other authors (AZ, RS, IJS, CH, WS, XC, MG, BJD, NL) have no disclosures and report no conflicts of interest., (© 2024 The Author(s).)